Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3164530 in advanced or metastatic cancer
NCT02221882Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2014
- Primary completion
- Mar 2017
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LY3164530 in cancer and metastatic cancer, sponsored by Eli Lilly and Company. Primary endpoint: Maximum Tolerated Dose. Started Aug 2014; status: completed.
02
Drugs
LY3164530
03
Conditions
cancermetastatic cancer
Beyond the preview
Go deeper on NCT02221882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02221882.